EBS Emergent Biosolutions, Inc.
XNYS
6.33
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
EBS
$6.33
—
Key stats
$6.33
Pre-market
$6.43
+1.42%
- 52-Week Range
- $4.36 – $14.06
- YTD
- -49.36%
- IV Rank (30D)
- 75.03
- Straddle Price
- $1.77
- P/C Vol Ratio
- 1.51
- Market Cap
- $0.3B
- Open
- $6.28
- Day Range
- $6.14 – $6.40
- Volume
- 485,438
- Prev Close
- $6.23
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.53 |
| Cost of Equity (CAPM) | 13.40% (VRP-adj) |
| WACC | 8.37% |
| Volatility Risk Premium | +138.8pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +1.4% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.01 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | -51.8% |
| Book / Price | 97.3% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 55.9% |
| FCF Margin (TTM) | 11.2% |
| Debt / Equity | 1.70 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $6.29 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $6.67 |
| Bollinger Width / SMA20 | 319.4% (drives anchor stability) |
| Net Debt | $0.4B |
| Market Cap | $0B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$38.35
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $17.81 | 32% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.5× · 3 peers |
| Peer EV/EBITDA | $73.52 | 19% | median 19.2× · 3 peers |
| Peer P/B | $21.66 | 25% | median 3.5× · 3 peers |
| Peer P/S | $54.34 | 25% | median 3.9× · 3 peers |
| Market Anchor (SMA50) | $6.29 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $6.78 | 0% | 6 strikes · skew -0.89 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $0.3B
- Employees
- 900
- List Date
- 2006-11-15
- CIK
- 0001367644
- Next Earnings
- 2026-11-02 (After-Close)
- EPS Forecast
- ($0.45) (1 est.)
- Headquarters
- Gaithersburg, MD
- Homepage
- https://www.emergentbiosolutions.com
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXA…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 14.77% | -2.44% | 9.73% | -35.52% | 9.54% | -9.35% | -2.21% |
| Feb | -17.09% | -12.03% | -9.30% | 95.76% | -28.69% | -30.40% | -0.29% |
| Mar | -9.09% | -1.13% | -14.10% | -25.37% | -28.84% | -7.68% | -14.37% |
| Apr | -24.21% | -25.79% | -9.81% | -18.26% | 12.66% | -1.79% | -11.20% |
| May | -1.53% | -2.43% | -3.83% | 195.34% | 28.46% | 7.67% | 37.28% |
| Jun | 2.02% | -3.51% | -10.37% | 11.62% | 1.27% | -1.30% | -0.04% |
| Jul | 2.92% | 8.83% | -9.11% | 80.03% | -10.91% | -14.20% | 9.59% |
| Aug | -1.00% | -29.83% | -40.71% | -21.38% | 47.42% | -17.68% | -10.53% |
| Sep | -21.35% | -11.40% | -33.07% | 12.99% | 7.43% | 6.11% | -6.55% |
| Oct | -13.34% | -1.00% | -33.86% | 6.97% | 35.80% | -0.47%* | -0.98% |
| Nov | -11.64% | -41.20% | 9.18% | 10.96% | 6.48% | -- | -5.24% |
| Dec | -0.37% | 0.00% | 0.42% | -2.85% | 14.55% | -- | 2.35% |
| Total | -59.73% | -76.65% | -82.62% | 368.11% | 90.39% | -54.65% | 30.81% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $6.67
SMA 50: $6.29
SMA 200: $8.13
Current: $6.34
EMA 12: $6.48
EMA 26: $6.54
MACD: -0.0632 | Signal: -0.0924
BULLISH
ADX (14): 16.36
RANGE
+DI: 21.47
−DI: 25.64
Momentum Oscillators
RSI (14): 45.56
NEUTRAL
Stoch %K: 17.62
Stoch %D: 14.26
Williams %R: -75.37
Volume & Volatility
BB Upper: $7.38
BB Lower: $5.96
NEUTRAL
OBV: -26,508,761
Vol SMA 20: 1,029,082
Vol ROC: -48.97%
ATR: $0.37
True Range: $0.26
HV 20: 74.9%
HV 30: 67.0%
HV 60: 97.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: EBS CURRENT PRICE: $7.98
Executive Summary Overall Assessment: NEUTRAL (6/10) Key Drivers: Positive news sentiment, technical momentum signals, and beta analysis. Primary Risks: High volatility, potential for breakouts/breakdowns, and mixed signals from RSI and MACD.
Investment Thesis: EBS presents a medium-risk opportunity with potential for upside movement. The recent FDA approval and positive news headlines suggest a bullish narrative, while the technical indicators show momentum building. However, the high volatility and mixed signals from RSI and MACD warrant caution.
Recent News Sentiment Impact: The positive news sentiment has contributed to the overall bullish tone, driving price up 10% in the past month. The recent FDA approval has boosted investor confidence, making it essential to monitor potential follow-up catalysts.
Technical Analysis Trend Direction: Uptrend (Short-term), Consolidation (Medium-term) Support/Resistance Levels:
- SMA 20: $8.24
- Lower Bollinger Band: $7.51
Momentum Signals: RSI Interpretation: Neutral (46.05, not overbought or oversold) MACD Signal: Bearish (Histogram -0.11), potential for reversal
Bollinger Bands Position: Squeeze (Price approaching upper band) Volume Analysis:
- Volume SMA 20: 986178.20
- On-Balance Volume (OBV): 14548526.47
- Volume Rate of Change: 24.43%
News & Sentiment Analysis Recent Headlines Summary: EBS has received FDA approval for NARCAN Nasal Spray Multipacks, and the news sentiment is overwhelmingly positive.
Sentiment Assessment: Positive (Aggregate sentiment from last 10 news articles)
Catalyst Identification: Upcoming events: Monitor earnings announcements, regulatory changes, and product launches.
Market Narrative: The positive news headlines align with the technical signals, suggesting a continuation of the uptrend. However, the high volatility and mixed RSI/MACD signals warrant caution.
Risk & Volatility Assessment Beta Interpretation: High risk (beta 1.42 vs SPY)
Volatility Regime: Current volatility is above historical levels
Options Market Signals: IV Rank: Medium (63.5%) Put/Call Volume Ratio: Bearish (1.67) Market Expectation: Options market pricing $1.07 move by expiration
Downside Protection: Support levels to monitor: SMA 20 ($8.24) and Lower Bollinger Band ($7.51)
Market Context & Positioning Sector Performance: Biotech sector has been trending up, driving EBS' price movement.
Institutional Activity: Monitor volume patterns suggesting institutional interest.
Correlation Analysis: R-squared interpretation: 0.21 (indicating a relatively weak correlation with the market)
Relative Valuation: EBS is trading within a defined range, with recent price movements driven by positive news and technical momentum signals.
Key Levels & Action Items Critical Price Levels:
- SMA 20 ($8.24)
- Lower Bollinger Band ($7.51)
Breakout/Breakdown Levels:
- Upper Bollinger Band ($8.97) as a potential resistance level
- $8.50 as a potential support level
Time-Sensitive Catalysts: Monitor earnings announcements, regulatory changes, and product launches.
Risk Management: Stop-loss levels to consider: SMA 20 ($8.24) and Lower Bollinger Band ($7.51)
This comprehensive analysis provides an objective assessment of EBS' current market situation, highlighting the key drivers, primary risks, and potential catalysts.
Generated
News
All EBS news →
Earnings History
17 of 25 under expected move
Avg Expected Move
19.04%
Avg Actual Move
19.20%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | After-Close | 8.60% | 4.54% | 0.53x | Within |
| 2021-04-29 | After-Close | 14.27% | 3.44% | 0.24x | Within |
| 2021-07-29 | After-Close | 11.35% | 1.04% | 0.09x | Within |
| 2021-11-04 | After-Close | 10.85% | 37.07% | 3.42x | Exceeded |
| 2022-01-10 | After-Close | 1.59% | 1.37% | 0.86x | Within |
| 2022-02-24 | After-Close | 9.33% | 6.38% | 0.68x | Within |
| 2022-04-28 | After-Close | 11.64% | 11.55% | 0.99x | Within |
| 2022-08-01 | After-Close | 15.16% | 11.60% | 0.77x | Within |
| 2022-11-08 | After-Close | 10.29% | 34.87% | 3.39x | Exceeded |
| 2023-01-09 | After-Close | 10.27% | 4.03% | 0.39x | Within |
| 2023-02-27 | After-Close | 17.50% | 11.57% | 0.66x | Within |
| 2023-05-09 | After-Close | 14.54% | 11.44% | 0.79x | Within |
| 2023-08-08 | After-Close | 18.33% | 17.78% | 0.97x | Within |
| 2023-11-08 | After-Close | 23.98% | 2.71% | 0.11x | Within |
| 2024-03-06 | After-Close | 46.32% | 15.03% | 0.32x | Within |
| 2024-05-01 | After-Close | 20.73% | 70.98% | 3.42x | Exceeded |
| 2024-08-06 | After-Close | 28.14% | 41.99% | 1.49x | Exceeded |
| 2024-11-06 | After-Close | 23.91% | 19.57% | 0.82x | Within |
| 2025-03-03 | After-Close | 50.51% | 6.44% | 0.13x | Within |
| 2025-05-07 | After-Close | 15.30% | 34.18% | 2.23x | Exceeded |
| 2025-08-06 | After-Close | 17.41% | 36.65% | 2.11x | Exceeded |
| 2025-10-29 | After-Close | 27.66% | 36.60% | 1.32x | Exceeded |
| 2026-02-26 | After-Close | 32.21% | 26.58% | 0.83x | Within |
| 2026-04-30 | After-Close | 19.14% | 2.92% | 0.15x | Within |
| 2026-08-05 | After-Close | 16.91% | 29.58% | 1.75x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
EBS Options Activity & IV Rank
EBS IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 109.9%
7-DTE IV: —
Expected Move: $1.77
7-DTE Move: $1.77
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 76
Put Volume: 115
P/C Volume: 1.513
BEARISH
Call OI: 1,180
Put OI: 217
P/C OI: 0.184
Total OI: 1,397
ATM Options Pricing
ATM Call: $1.25
ATM Put: $0.53
Call %: 19.7%
Put %: 8.3%
Chain Summary
Chain Volume: 2,079
Chain OI: 13,517
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 36th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
36%
vs own history
GEX tilt
+0.47
OI-weighted, today
Vanna tilt
+0.62
δ-sensitivity to IV
Charm tilt
-0.61
δ-decay vs time
Vanna tilt +0.62: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.61: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 11 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 135.5% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)75.0HighOct 26
Straddle Price (30 DTE)$1.77Oct 26
Beta Analysis
Risk Metrics
Beta: 1.0602
Alpha: -24.81%
Correlation: 0.1699
R-Squared: 2.9%
Stock Volatility: 79.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own EBS
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $9.0M | #1645 of 3716 | +101.5% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $5.7M | #1382 of 3138 | +4.1% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $8K | #4101 of 4729 | -10.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
EBS Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 55,325,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
7 filers$5.79M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.42M | 41.82% | 2026-06-30 |
| 2 | GROUP ONE TRADING LLC Custodian | $963.70K | 16.65% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $850.57K | 14.70% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $724.87K | 12.52% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $552.24K | 9.54% | 2026-06-30 |
| 6 | Wolverine Trading, LLC Custodian | $272.67K | 4.71% | 2025-09-30 |
| 7 | Raiffeisen Bank International AG | $3.35K | 0.06% | 2026-06-30 |
5 filers$1.72M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $785.21K | 45.65% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $506.99K | 29.48% | 2026-06-30 |
| 3 | Wolverine Trading, LLC Custodian | $353.13K | 20.53% | 2025-09-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $63.69K | 3.70% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $10.89K | 0.63% | 2026-06-30 |
EBS Insider Trading (Form 4)
Latest: 2026-10-07Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Donald W DeGolyer | Director | Sell (S) | −17,800 | $7.09 | -$126.2K | EDGAR |
| 2026-10-05 | Paul Anthony Williams | SVP, Products Business | Sell (S) | −3,000 | $6.53 | -$19.6K | EDGAR |
| 2026-07-02 | Paul Anthony Williams | SVP, Products Business | Sell (S) | −3,000 | $8.40 | -$25.2K | EDGAR |
| 2026-06-10 | William Hartzel | SVP, Bioservices | Tax (F) | −1,741 | $8.00 | -$13.9K | EDGAR |
| 2026-06-10 | Coleen Glessner | EVP, Quality & Ethics, and CPL | Tax (F) | −2,018 | $8.00 | -$16.1K | EDGAR |
| 2026-06-10 | Richard S Lindahl | EVP, Chief Financial Officer | Tax (F) | −3,964 | $8.00 | -$31.7K | EDGAR |
| 2026-06-10 | Paul Anthony Williams | SVP, Products Business | Tax (F) | −694 | $8.00 | -$5.6K | EDGAR |
| 2026-05-04 | Ronald Richard | Director | Award (A) | +25,344 | — | EDGAR | |
| 2026-05-04 | Neal Franklin Fowler | Director | Award (A) | +25,344 | — | EDGAR | |
| 2026-05-04 | Marvin L White | Director | Award (A) | +25,344 | — | EDGAR | |
| 2026-05-04 | Donald W DeGolyer | Director | Mixed | +9,863 | $8.40 | -$130.0K | EDGAR |
| 2026-05-04 | John D Fowler Jr | Director | Award (A) | +25,344 | — | EDGAR | |
| 2026-05-04 | Sujata Tyagi Dayal | Director | Mixed | +11,583 | $8.40 | -$115.6K | EDGAR |
| 2026-05-04 | Zsolt Harsanyi | Chairman | Award (A) | +25,344 | — | EDGAR | |
| 2026-05-04 | Keith Katkin | Director | Mixed | +9,863 | $8.28 | -$128.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
EBS Insider Holdings
17 insiders · @ $6.34
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Joseph C Papa | President and CEO | 493,153 | $3.13M | $349.8K | 6 | 2026-05-01 |
| 2 | Richard S Lindahl | EVP, Chief Financial Officer | 374,083 | $2.37M | $112.4K | 32 | 2026-06-10 |
| 3 | Coleen Glessner | EVP, Quality & Ethics, and CPL | 202,201 | $1.28M | -$306.1K | 20 | 2026-06-10 |
| 4 | William Hartzel | SVP, Bioservices | 185,558 | $1.18M | $0 | 18 | 2026-06-10 |
| 5 | Simon C Lowry | SVP, R&D, CMO | 177,914 | $1.13M | $0 | 5 | 2026-05-01 |
| 6 | Jessica Perl | SVP, General Counsel, Corp Sec | 165,286 | $1.05M | $0 | 5 | 2026-05-01 |
| 7 | Neal Franklin Fowler | Director | 160,847 | $1.02M | -$204.1K | 5 | 2026-05-04 |
| 8 | Paul Anthony Williams | SVP, Products Business | 156,098 | $989.7K | -$78.5K | 22 | 2026-10-05 |
| 9 | Zsolt Harsanyi | Chairman | 149,076 | $945.1K | -$5.91M | 35 | 2026-05-04 |
| 10 | Louis W Sullivan | Director | 139,098 | $881.9K | -$5.64M | 30 | 2025-05-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
EBS Board & Officers
As of SEC filings through Oct 7, 2026Directors 10
- Ronald Richard · since Nov 14, 2006
- Zsolt Harsanyi · since Nov 14, 2006
- Kathryn C Zoon · since Nov 8, 2016
- Marvin L White · listed since Oct 2020
- Keith Katkin · since Apr 1, 2022
- Sujata Tyagi Dayal · since Jul 15, 2022
- Donald W DeGolyer · since Oct 1, 2023
- Neal Franklin Fowler · since Oct 1, 2023
- Joseph C Papa · since Feb 21, 2024
- John D Fowler Jr · since Mar 1, 2026
Officers 9
- Joseph C Papa · President and CEO · since Feb 21, 2024
- Richard S Lindahl · EVP, Chief Financial Officer · since Mar 26, 2018
- Jessica Perl · SVP, General Counsel, Corp Sec · since Oct 29, 2024
- Coleen Glessner · EVP, Quality & Ethics, and CPL · since Mar 14, 2022
- Stephanie Duatschek · EVP, Cgo · since Aug 5, 2026
- Paul Anthony Williams · SVP, Products Business · since Jan 9, 2023
- Zsolt Harsanyi · Chairman · listed since May 2023
- William Hartzel · SVP, Bioservices · since Aug 8, 2023
- Simon C Lowry · SVP, R&D, CMO · since Nov 18, 2024
Changes in the last 10 years (42)
| Aug 5, 2026 | Stephanie Duatschek became EVP, Cgo |
| Mar 1, 2026 | John D Fowler Jr became a director |
| Nov 7, 2025 | The company announced the departure of Louis W Sullivan from the board in an SEC filing |
| Nov 18, 2024 | Simon C Lowry became SVP, R&D, CMO |
| Oct 29, 2024 | Jessica Perl became SVP, General Counsel, Corp Sec |
| Jul 30, 2024 | The company announced the departure of Jennifer Lynne Fox as EVP, Ext Aff, GC, Corp Sec in an SEC filing |
| Feb 21, 2024 | Joseph C Papa became a director |
| Feb 21, 2024 | Joseph C Papa became President and CEO |
| Oct 1, 2023 | Neal Franklin Fowler became a director |
| Oct 1, 2023 | Donald W DeGolyer became a director |
| Aug 16, 2023 | The company announced the departure of Jerome M Hauer from the board in an SEC filing |
| Aug 8, 2023 | William Hartzel became SVP, Bioservices |
| Aug 8, 2023 | The company announced the departure of Adam Havey as EVP, Business Operations in an SEC filing |
| Jun 24, 2023 | H Haywood Miller III became Interim CEO |
| Jun 23, 2023 | The company announced the departure of Robert Kramer from the board in an SEC filing |
| Jun 23, 2023 | The company announced the departure of Robert Kramer as President and CEO in an SEC filing |
| May 30, 2023 | Zsolt Harsanyi first listed as Chairman in an SEC filing |
| Mar 23, 2023 | The company announced the departure of Atul Saran as EVP, Chief Strat & Dev Officer in an SEC filing |
| Jan 9, 2023 | Paul Anthony Williams became SVP, Products Business |
| Jul 15, 2022 | Sujata Tyagi Dayal became a director |
| Apr 1, 2022 | Keith Katkin became a director |
| Mar 14, 2022 | Coleen Glessner became EVP, Quality & Ethics, and CPL |
| Mar 2, 2022 | Atul Saran listed as EVP, Chief Strat & Dev Officer (previously EVP, Corp Dev, GC & Secretary) in SEC filings |
| Mar 1, 2022 | Jennifer Lynne Fox became EVP, Ext Aff, GC, Corp Sec |
| Feb 15, 2022 | The company announced the departure of Fuad El-Hibri from the board in an SEC filing |
| Jan 13, 2022 | The company announced the departure of Fuad El-Hibri as Chairman in an SEC filing |
| Feb 26, 2021 | Fuad El-Hibri no longer listed as a 10% owner in SEC filings |
| Oct 5, 2020 | Marvin L White first listed as a director in an SEC filing |
| May 21, 2020 | Karen L. Smith became EVP, Chief Medical Officer |
| May 12, 2020 | Robert Kramer first listed as a director in an SEC filing |
| Feb 27, 2020 | Sean Kirk first on file as EVP, Manufacturing & Tech Ops |
| May 10, 2019 | Robert Kramer listed as President and CEO (previously President and COO) in SEC filings |
| Mar 19, 2019 | Seamus Mulligan became a director |
| Jun 7, 2018 | Daniel Abdun-Nabi listed as CEO (previously President & CEO) in SEC filings |
| May 10, 2018 | Robert Kramer listed as President and COO (previously EVP, Administration and CFO) in SEC filings |
| Mar 26, 2018 | Richard S Lindahl became EVP, Chief Financial Officer |
| Mar 1, 2018 | Robert Kramer listed as EVP, Administration and CFO (previously EVP, Corproate Services Div) in SEC filings |
| Sep 12, 2017 | Adam Havey listed as EVP, Business Operations (previously EVP, Biodefense Divison) in SEC filings |
| Jul 20, 2017 | Katherine Strei became EVP, Chief HR Officer |
| Jul 20, 2017 | Atul Saran became EVP, Corp Dev, GC & Secretary |
| Mar 2, 2017 | Robert Kramer listed as EVP, Corproate Services Div (previously EVP, Corporate Services Divisi) in SEC filings |
| Nov 8, 2016 | Kathryn C Zoon became a director |
Not reported recently (8)
- H Haywood Miller III · Last reported as Interim CEO in an SEC filing dated Jul 18, 2023
- Katherine Strei · Last reported as EVP, Chief HR Officer in an SEC filing dated Mar 2, 2023
- George A Joulwan · Last reported as a director in an SEC filing dated May 31, 2022
- Karen L. Smith · Last reported as EVP, Chief Medical Officer in an SEC filing dated May 11, 2021
- Sean Kirk · Last reported as EVP, Manufacturing & Tech Ops in an SEC filing dated Apr 1, 2021
- Sue Bailey · Last reported as a director in an SEC filing dated Mar 8, 2021
- Seamus Mulligan · Last reported as a director in an SEC filing dated Mar 21, 2019
- Daniel Abdun-Nabi · Last reported as a director in an SEC filing dated Mar 4, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
EBS Proposed Insider Sales (Form 144)
Latest: 2026-10-07
? Form 144 Guide
Last 30d:
2 filings
· $146K notice value
· Last 90d:
2 filings
· $146K notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
DONALD DEGOLYER (1, $126K) · PAUL WILLIAMS (1, $20K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-07 | DONALD DEGOLYER | Director | 17,800 | $126.1K | 2026-10-07 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-01 | PAUL WILLIAMS | Officer | 3,000 | $19.6K | 2026-10-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-01 | PAUL WILLIAMS | Officer | 3,000 | $25.2K | 2026-07-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-01 | SUJATA TYAGI DAYAL | Director | 13,761 | $115.6K | 2026-05-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-01 | KATHRYN ZOON | Director | 17,202 | $144.5K | 2026-05-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-01 | DONALD DEGOLYER | Director | 15,481 | $130.1K | 2026-05-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-30 | KEITH KATKIN | Director | 15,481 | $128.1K | 2026-04-30 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-01 | PAUL WILLIAMS | Officer | 4,000 | $33.8K | 2026-04-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-01-07 | LOUIS W SULLIVAN | Director | 25,748 | $360.1K | 2026-01-07 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-12-22 | LOUIS W SULLIVAN | Director | 104,695 | $1.34M | 2025-12-22 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
99 ETFs hold EBS
25 shown · $2.06B total exposure · 0.15% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXUS Vanguard Total International Stock ETF | Vanguard | 0.09% | $566.0M | — | 2026-09-30 |
| 2 | VEA Vanguard FTSE Developed Markets ETF | Vanguard | 0.12% | $373.5M | — | 2026-09-30 |
| 3 | IEFA iShares Core MSCI EAFE ETF | iShares (BlackRock) | 0.14% | $272.4M | $189.0B | 2026-10-23 |
| 4 | EFA iShares MSCI EAFE ETF | iShares (BlackRock) | 0.17% | $129.0M | $76.4B | 2026-10-23 |
| 5 | VGK Vanguard FTSE Europe ETF | Vanguard | 0.25% | $92.2M | — | 2026-09-30 |
| 6 | VEU Vanguard FTSE All-World Ex-US ETF | Vanguard | 0.09% | $91.2M | — | 2026-09-30 |
| 7 | SPDW State Street® SPDR® Portfolio Developed World ex-US ETF | SPDR (State Street) | 0.12% | $50.7M | $40.7B | 2026-10-23 |
| 8 | EFV iShares MSCI EAFE Value ETF | iShares (BlackRock) | 0.17% | $50.4M | $30.4B | 2026-10-23 |
| 9 | IXUS iShares Core MSCI Total International Stock ETF | iShares (BlackRock) | 0.09% | $50.1M | $57.1B | 2026-10-23 |
| 10 | EZU iShares MSCI Eurozone ETF | iShares (BlackRock) | 0.50% | $45.6M | $9.1B | 2026-10-23 |
| 11 | VYMI Vanguard International High Dividend Yield ETF | Vanguard | 0.20% | $45.6M | — | 2026-09-30 |
| 12 | IDEV iShares Core MSCI International Developed Markets ETF | iShares (BlackRock) | 0.13% | $42.8M | $33.7B | 2026-10-23 |
| 13 | EWO iShares MSCI Austria ETF | iShares (BlackRock) | 20.75% | $35.6M | $171.7M | 2026-10-23 |
| 14 | VT Vanguard Total World Stock ETF | Vanguard | 0.03% | $34.1M | — | 2026-09-30 |
| 15 | EUFN iShares MSCI Europe Financials ETF | iShares (BlackRock) | 1.08% | $32.6M | $3.0B | 2026-10-23 |
| 16 | EFG iShares MSCI EAFE Growth ETF | iShares (BlackRock) | 0.17% | $25.4M | $14.9B | 2026-10-23 |
| 17 | IEUR iShares Core MSCI Europe ETF | iShares (BlackRock) | 0.24% | $22.4M | $9.4B | 2026-10-23 |
| 18 | AVUV Avantis U.S. Small Cap Value ETF | Avantis | 0.06% | $18.9M | $32.2B | 2026-10-23 |
| 19 | ACWX iShares MSCI ACWI ex U.S. ETF | iShares (BlackRock) | 0.10% | $17.7M | $17.6B | 2026-10-23 |
| 20 | ESGD iShares ESG Aware MSCI EAFE ETF | iShares (BlackRock) | 0.12% | $14.5M | $11.8B | 2026-10-23 |
| 21 | IVLU iShares MSCI Intl Value Factor ETF | iShares (BlackRock) | 0.27% | $12.1M | $4.5B | 2026-10-23 |
| 22 | ACWI iShares MSCI ACWI ETF | iShares (BlackRock) | 0.04% | $11.7M | $32.6B | 2026-10-23 |
| 23 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.10% | $10.7M | $10.4B | 2026-10-23 |
| 24 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $10.3M | — | 2026-09-30 |
| 25 | IMTM iShares MSCI Intl Momentum Factor ETF | iShares (BlackRock) | 0.22% | $9.0M | $4.1B | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-3.47
TTM Revenue
$770.20M
TTM Net Income
$-176.80M
TTM Op. Cash Flow
$97.70M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $234.30M | $-180.20M | $-3.49 | $56.10M |
| Q1 '26 | 2026-03-31 | $156.10M | $6.80M | $0.07 | $-33.80M |
| Q4 '25 | 2025-12-31 | $148.70M | $-54.60M | $-0.96 | $77.70M |
| Q3 '25 | 2025-09-30 | $231.10M | $51.20M | $0.91 | $-2.30M |
| Q2 '25 | 2025-06-30 | $140.90M | $-12.00M | $-0.22 | $106.40M |
| Q1 '25 | 2025-03-31 | $222.20M | $68.00M | $1.19 | $-11.20M |
| Q4 '24 | 2024-12-31 | $194.70M | $-31.30M | $-0.57 | $-79.90M |
| Q3 '24 | 2024-09-30 | $293.80M | $114.80M | $2.06 | $153.70M |
| Q2 '24 | 2024-06-30 | $254.70M | $-283.10M | $-5.38 | $47.50M |
| Q1 '24 | 2024-03-31 | $300.40M | $9.00M | $0.17 | $-62.60M |
| Q4 '23 | 2023-12-31 | $276.60M | $-49.50M | $-0.88 | $32.10M |
| Q3 '23 | 2023-09-30 | $270.50M | $-263.40M | $-5.08 | $60.00M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.03
P/S
0.46
EV/EBITDA
3.42
EV/Sales
1.03
ROE
-51.8%
ROA
-15.8%
Div Yield
0.00%
FCF Yield
27.85%
Debt/Equity
1.70
Current Ratio
—
Market Cap
$350.76M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
9.29M
SI % of Float
18.48%
Days to Cover
8.31
Short Vol Ratio
49.2%
Free Float
50.30M
Float %
98.1%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-13